


文档简介
1、Product Data SheetZosuquidar trihydrochlorideCat. No.: HY-50671CAS No.: 167465-36-3分式: CHClFNO分量: 636.99作靶点: P-glycoprotein作通路: Membrane Transporter/Ion Channel储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 H2O : 5 mg/mL (7.85 mM; Need ultrasonic)DMSO : 1 mg/mL (1.57
2、 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 1.5699 mL 7.8494 mL 15.6988 mL5 mM 0.3140 mL 1.5699 mL 3.1398 mL10 mM 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;旦配成溶液,请分装保存,避免反复冻融造成的产品失效。储备液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 储存时,请在 6 个内使,-20C 储存时,请在 1 个内使。体内实验 1. Zosuquidar is dissolv
3、ed in 20% ethanol-saline5.BIOLOGICAL ACTIVITY物活性 Zosuquidar trihydrochlorideP-糖蛋的抑制剂, Ki值为59 nM。IC & Target Ki: 59nM (P-glycoprotein)1.体外研究 Zosuquidar completely or partially restores drug sensitivity in all P-gp-expressing leukemia cell lines and enhancesthe cytotoxicity of anthracyclines (daunorub
4、icin, idarubicin, mitoxantrone) and gemtuzumab ozogamicin (Mylotarg) inprimary AmL blasts with active P-gp. In addition, P-gp inhibition by zosuquidar is found to be more potent thancyclosporine A in cells with highly active P-gp2.Page 1 of 2 www.MedChemE体内研究 Zosuquidar trihydrochloride is only mode
5、rately active as an inhibitor of P-gp at the blood-brain. An oral dose of 25mg/kg of zosuquidar trihydrochloride increases the brain concentrations by about 2.5-fold at 1 h and 5-fold at 24 h after paclitaxel administrationbarrier3. Zosuquidar enhances the brain uptake of nelfinavir in a dose-depend
6、entmanner. Brain tissue/plasma nelfinavir concentration ratios increase from 0.060.03 in the absence of zosuquidaradministration and 0.090.02 between 2 and 6 h after a 2 mg/kg intravenous dose of zosuquidar to 0.850.19 after6h and 1.580.67 after 20 mg/kg zosuquidar4.PROTOCOLCell Assay 2 Cells are cu
7、ltured in 96-well plates. Each drug of interest is added at escalating concentrations in the presence orabsence of either zosuquidar or CsA. After 48 hour incubation (except Mylotarg, 4 days incubation), 20 L of MTT isadded to each well for a further 4 hour incubation. The purple precipitate is diss
8、olved in 200 L DMSO, and the opticdensity (OD) is determined by the multi-well plate reader2.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Rats: Female Sprague-Dawley rats are used in the study. Zosuquidar solutions are prepared in 5% mannitol
9、andAdministration 34adjusted to pH 2.0 with concentrated HCl. Nelfinavir is infused (10 mg/kg/h) for up to 10 h with or withoutconcurrent administration of an intravenous bolus dose of 2, 6, or 20 mg/kg zosuquidar given at 4 h. Brain tissueand plasma are analyzed for both drug concentrations4.Mice:
10、A stock solution of 5 mg/mL of zosuquidar trihydrochloride is prepared in vehicle solution and diluted in sterilesaline. The vehicle solution consisted of 20 g/l mannitol and 1.5 g/l of glycine in water for injection and adjusted to apH of 2.7 with hydrochloric acid. P-gp knockout mice and wild type
11、 mice are used as a model for complete inhibitionof P-gp. Zosuquidar trihydrochloride is administered orally at 25 and 80 mg/kg 1 h before i.v. paclitaxel and i.v. at 20mg/kg 10 min and 1 h before paclitaxel. The concentrations of paclitaxel in plasma and tissues and of zosuquidartrihydrochloride in
12、 plasma are quantified by high-performance liquid chromatography3.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Cancer Cell. 2017 Apr 10;31(4):501-515.e8. Drug Metab Dispos. 2017 May;45(5):449-456. J Pharm Biomed Anal. 2012 Jul;66:232-9. J
13、 Chromatogr B Analyt Technol Biomed Life Sci. 2018 May 31;1092:72-81. Biomed Res Int. 2014;2014:850493.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Cripe LD, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients wit
14、h newly diagnosed acute myeloidleukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood.?2012. Tang R, et al. Zosuquidar?restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AmL). BMC Cancer.?2008 Feb 13;8:51.?3. Kemper EM, et a
15、l. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.Cancer Chemother Pharmacol. 2004 Feb;53(2):173-8.Page 2 of 3 www.MedChemE4. Anderson BD, et al. Dependence of nelfinavir brain uptake on dose and tissue concentratio
16、ns of the selective P-glycoprotein inhibitor zosuquidar in rats.Drug Metab Dispos. 2006 Apr;34(4):653-9.5. Hou J, et al. Quantitative determination and pharmacokinetic study of the novel anti-Parkinsons disease candidate drug FLZ in rat brain by highperformance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Ana
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 六安2025年安徽六安市金安区消防救援局招聘政府专职消防员6人笔试历年参考题库附带答案详解
- 二零二五版全新股权法人转让协议
- 私人承包经营餐厅合同书
- 二零二五版小区物业管理服务合同
- 二零二五管理物业服务委托合同
- 初一体育与健康基础知识
- 2025年租赁合同续签示范文本
- 2025劳动合同薪酬结构范本参考
- 体温与血压的评估与护理
- 2025装饰装修工程补充合同新版(合同版本)
- 老年人常见病防治与中医养生课件
- 从十四五规划看数字化转型课件
- 第2章 轨道几何形位《铁路轨道》
- 购买办公设备申请表
- 危险性较大作业安全许可审批表
- 肥矿关于单轨吊管理的规定
- 绩效评价师考试-随机题库
- 融资担保公司会计培训
- 南京被联合国评为No.1世界文学之都课件
- 叉车日常维护保养检查记录表
- 施工总平面布置和临时设施布置技术标
评论
0/150
提交评论